The Food and Drug Administration expanded the approval of weight loss drug Zepbound to treat obstructive sleep apnea in ...

Novo Nordisk (NVO) increased valuation gap with Eli Lilly (LLY) after its Phase 3 data for next-gen weight loss drug ...

Santa Claus will soon be on his way delivering presents to kids around the world. But could the jolly gift-giver bring ...

Novo Nordisk ’s big bet to improve on the success of its weight-loss drug franchise hit a stumbling block Friday, wiping out ...

Shares in Novo Nordisk fell yesterday, after it revealed disappointing results from a late-stage trial of its next-generation obesity drug CagriSema, wiping as much as $125bn (€120bn) off its market ...

The Food and Drug Administration today approved Eli Lilly’s weight-loss treatment, Zepbound, for obstructive sleep apnea, ...

The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and ...

News of a fresh licensing deal by a well-capitalized rival sent Viking Therapeutics ( VKTX 1.83%) stock into something of a tailspin this week. According to data compiled by S&P Global Market ...

A new study put Eli Lilly's Zepbound and Novo Nordisk's Wegovy to the test. Here's which one will help you lose more weight.

Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration ...